Clinical Trials Logo
  1. Home
  2. Thromboembolism
  3. NCT01541995
  4. Details
NCT01541995 Clinical Trial

Evaluation of Contrast Medium Enhanced Post-mortem CT in Virtual Autopsy

Thromboembolism Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01541995
Other study ID # VA-3 Contrast Medium
Secondary ID
Status Completed
Phase N/A
First received February 24, 2012
Last updated September 27, 2013
Start date April 2012

Study information
Verified date September 2013
Source Universitätsklinikum Hamburg-Eppendorf
Contact n/a
Is FDA regulated No
Health authority Ethics Commission Chamber of Physicians Hamburg: Germany
Study type Observational

Clinical Trial Summary

The study aims to compare the value of contrast medium enhanced post mortem CT to classic autopsy.

Recruitment information / eligibility
Status Completed
Enrollment 50
Est. completion date
Est. primary completion date August 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients dying in the ICU

- age >18y

Exclusion Criteria:

- relatives refusing to participation in the study

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Germany University Medical Center Hamburg-Eppendorf Hamburg

Sponsors (1)
Lead Sponsor Collaborator
Universitätsklinikum Hamburg-Eppendorf

Country where clinical trial is conducted

Germany, 

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism Phase 2
Active, not recruiting NCT05563883 - Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
Terminated NCT02475187 - Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
Recruiting NCT00982514 - Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008 N/A
Completed NCT01420809 - Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection N/A
Terminated NCT00206089 - Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events Phase 3
Completed NCT00014352 - Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer Phase 2
Completed NCT00000614 - Prevention of Recurrent Venous Thromboembolism (PREVENT) Phase 3
Active, not recruiting NCT05656963 - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Completed NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Completed NCT02935751 - Apixaban Discontinuation Prior to Major Surgery
Terminated NCT02579122 - REVIparin-BRIDging-in a General Practice Setting in GErmany
Completed NCT01696760 - Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology N/A
Completed NCT00986154 - Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Phase 3
Terminated NCT00662688 - Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer Phase 3
Completed NCT00260988 - A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery Phase 2/Phase 3
Terminated NCT00031837 - Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer Phase 3
Completed NCT03877770 - DVT After Cardiac Procedure
Completed NCT00024297 - Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters N/A
Recruiting NCT06118957 - Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery Phase 2